Notch signaling and MicroRNA: The dynamic duo steering between neurogenesis and glioblastomas

Zeeshan Javed1, Khushbukhat Khan2, Qamar Raza3, Haleema Sadia4, Faiez Ahmad Shah5, Touqeer Ahmad3, Angela Bentivegna6, Riccardo Bazzoni7, William N. Setzer8,9, Mohammed M Alshehri10, Sevgi Durna Daştan11,12, Javad Sharifi-Rad12*

1 Office of Research Innovation and Commercialization Department, Lahore Garrison University, Lahore, Pakistan
2 Atta-ur-Rahman School of Applied Biosciences (ASAB), National University of Sciences and Technology (NUST), H-12, Islamabad 44000, Pakistan
3 Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Pakistan
4 Department of biotechnology BUITEMS, Quetta, Pakistan
5 Department of Biotechnology, Quaid-i-Azam University, Islamabad, Pakistan
6 School of Medicine and Surgery, University of Milano-Bicocca Via Cadore, 48 - 20900 Monza (MB) Italy
7 Stem Cell Research Laboratory, Department of Medicine, University of Verona, Pz.LeScuro 10, 37134 Verona, Italy
8 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA
9 Aromatic Plant Research Center, 230 N 1200 E, Suite 100, Lehi, UT 84043, USA
10 Department of Pharmaceutical Care Services, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia
11 Department of Biology, Faculty of Science, Sivas Cumhuriyet University, 58140, Sivas, Turkey
12 Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Correspondence to: javad.sharifrad@gmail.com

Received December 14, 2019; Accepted May 1, 2020; Published August 15, 2021

Doi: http://dx.doi.org/10.14715/cmb/2021.67.2.6

Copyright: © 2021 by the C.M.B. Association. All rights reserved.

Abstract: Notch signaling is an evolutionary conserved pathway that plays a central role in development and differentiation of eukaryotic cells. It has been well documented that Notch signaling is inevitable for neuronal cell growth and homeostasis. It regulates processes of differentiation from early embryonic stages to fully developed brain. To achieve this streamlined development of neuronal cells, a number of cellular processes are orchestrated by Notch signaling. Abrogated Notch signaling is related to several brain tumors, including glioblastomas. On the other hand, microRNAs are small molecules that play decisive roles in mediating and modulating Notch signaling. This review discusses the crucial role of Notch signaling in the development of the nervous system and how this versatile pathway interplays with microRNAs in glioblastoma. This review sheds light on the interplay between abrogated Notch signaling and miRNAs in the regulation of neuronal differentiation with special focus on miRNAs-mediated regulation of tumorigenesis in glioblastoma. Furthermore, it discusses different aspects of neurogenesis modulated by Notch signaling that could be exploited for the identification of new diagnostic tools and therapies for the treatment of glioblastoma.

Key words: Notch signaling; miRNAs; Glioblastoma; Tumorigenesis; Therapeutics.

Introduction

The alleles of Notch gene were first identified in Drosophila melanogaster, which showed a notched phenotype in the wings, in 1917 by T.H. Morgan and it was clear from the outset that it was involved in the most vital cellular developmental processes. It has been found in nearly all metazoan species and the number of its signaling ligands varies from species to species and cell to cell. In mammals, four Notch receptors are recognized, which orchestrate cellular processes ranging from development to homeostasis (1-4). The actions of Notch signaling are mainly intricated by ligand binding to the respective Notch receptor. This ligand-Notch receptor interaction triggers a cascade of molecular signaling that instigate the development and maturity of the stem cells during development and also in adulthood (5, 6). In neuronal stem cells (NSCs), Notch signaling is tissue-dependent and modulates neural processes including coupling of neuronal growth, differentiation and development of astrocytes (7-9).

This review brings to spotlight the essential role of Notch signaling in the development of the central nervous system (CNS). miRNAs are small molecules with a gene-regulatory role that interact with the Notch signaling cascade during neurogenesis, whose alteration may contribute to glioblastoma. The objectives of this review also include discussing ways in which the applications of the knowledge about this pathway can be extended for discovering unique and therapeutically beneficial tools for glioblastomas treatment.

Notch proteins and ligands

The cascade of Notch signaling requires binding of ligand to the Notch receptor for its activation. Upon
ligand-receptor interaction, the signaling initiates. In mammals, four Notch receptors exist: Notch1, Notch2, Notch3 and Notch4. These are single-pass transmembrane proteins that are located on the surface of the cell in hetero-oligomeric form. Like other transmembrane receptors, Notch receptors also possess an extracellular and an intracellular domain. The extra-cellular domain includes epidermal growth factor (EGF)-like repeats, which number varies among Notch receptors. These repeats play an essential role in receptor-ligand interaction (10, 11). Furthermore, to avoid ligand-free activation of these receptors, three cystine-rich LIN12/Notch repeats (LNR) are present next to EGF-like repeats. The intracellular domain of Notch receptors consists in six ankyrin/cdc10 repeats (which mediates protein-protein interaction), a RAM23 domain (located N-terminal to ankyrin repeats and facilitates protein-protein interaction) (12), two nuclear localization signals (N1 and N2), a PEST sequence (for negative modulation of protein stability) and a transactivation domain (TAD) (13). Interestingly, Notch1 and Notch3 receptors present a RE/AC (repression/activation) region, located at C-terminal to the ankyrin repeats, required for Notch1 ability to activate and for Notch 3 IC's ability to repress a HES promoter. The interaction between the RE/AC region and the ankyrin repeat region provides a basis for interpreting the difference in HES activation between structurally similar Notch receptors. Additionally, each Notch receptor includes three proteolytic cleavage sites: S1, S2 and S3 (14). The Notch receptor is synthesized as single precursor protein; then, the cleavage on these sites facilitates maturation, activation and transportation of the receptor. The cleavage at S1 site at the extracellular domain by the proteolytic activity of furin-like convertase occurs in the Golgi system during intracellular maturation, while cleavages at S2 and S3 sites occur upon ligand-receptor interaction. The ligands of Notch receptors share common structural features with receptor’s EGF-like repeats and a distal Cys-rich region called the Delta/Serrate/Lag-2 (DSL) domain. For this reason the ligands are collectively referred to as DSL and include: Delta1/3/4 (Dll) and Jagged1-2 (13).

**Notch signaling activation: The pathway’s overview**

Signal transduction through Notch receptors is triggered upon ligand-receptor interaction, which is followed by a conformational change of the receptor’s extracellular portion and detachment of its intracellular portion via proteolytic cleavage (15). The receptor is resistant to proteolytic cleavage prior to ligand binding. The receptor activity at the intracellular domain is monitored by HDAC and a set of co-repressors including NCoR and SMRT (16, 17). These co-repressors act to block gene activation by Notch receptors. Upon cleavage at two sites (S3 and S4) by a presenilin-dependent-secretase complex, the receptor’s active form, the Notch intracellular domain (NICD), translocates into the nucleus where it binds to the CSL transcription factor’s family ( acronym for CBF1/Suppressor of hairless/LAG in humans, Drosophila and C. elegans, respectively). CSL proteins function as co-repressors of the target genes in the absence of Notch activity, but upon Notch interaction, they transform themselves into co-activators (Figure 1). Two enzymes that actively participate in promoting the transcription of target genes are histone acetyltransferases (HAT) CBP/p300 and PCAF/GCN5, which mediate chromatin relaxation and recruit RNA polymerase II enzyme (3). This results in the expression of Notch targeted genes such as the transcription regulators Hairy Enhancer of Split (HES) and HES-related proteins (Hey). It has been confirmed through studies that the expression of these transcription regulators mediates the stemness and *de-novo* regeneration of (NSCs) (16). Other Notch target genes are c-Myc, cyclin D1, p21, NF-kB, and SOX2 (18).

**Notch signaling in neuronal regulation**

Several molecules and mechanisms are involved in the regulation of Notch signaling at the transcriptional and post-transcriptional level. For instance, the Hes gene family curbs gene expression at the transcription level in neuronal cells by maintaining asymmetric cell division through the use of a feedback loop system. At post-transcriptional level, other mechanisms including glycosylation, proteolysis, endocytosis, and degradation modulate Notch signaling (19).

Proneural genes such as ASCL1 and NEUROG2 are demonstrated to drive neurogenesis through the
activation of basic helix loop helic (bHLH) transcription factors (17, 20). Additionally, these genes can also facilitate the regulation of neurogenesis and the differentiation process by inducing the Notch ligands’ expression such as Delta like 1 (Dll1) (21). The role of Notch signaling is illustrated in Figure 2. Some studies have also evidenced the proneural genes’ involvement with the synthesis of the neuron differentiating genes such as NeuroD. However, lateral Notch signaling can be modulated via the transcriptional feedback loop (22). NICD has positive impact on the expression of transcription factors Hes1 and Hes5 which consequently lead to suppression of proneural genes such as Ascl1 and Neurog2. Thus, it brings about inhibition of lateral Notch signaling and the neuronal differentiation process. The promoter complex NICD-RBPj-Hes is primarily involved in repressing differentiation, but without the involvement of this promoter complex, the early differentiation of embryonic NSCs is inconceivable (23, 24). Forward and backward loops created by Hes-mediated oscillations bring the active synthesis and differentiation of Ngn2 and Dll1 mRNA expression to a halt (23, 24).

Imayoshi et al. determined through the use of time lapse-imaging analysis of transcription factors Ascl1/ Mash1, Hes1, and Olig2 that these factors are expressed in an oscillatory manner by neural progenitor cells. According to them, each factor dominates at different stages, which facilitate fate determination and proliferation of neuronal progenitor cells (NPC). For instance, oscillating Ascl1 expression is necessary for NPC proliferation but its sustained expression is a pre-requisite for fate determination. Altogether, proneural genes promote asymmetric cell division in neuronal cells, facilitating production along with reservation of NSCs via lateral Notch signaling (24).

Notch signaling: Post-translational modifications as modulators in neuronal differentiation and neurogenesis

Post-translational modifications modulate the message transduction through Notch signaling at many levels. For instance, N-O linked glycosylation is a prerequisite for Notch signaling for its functioning during early biogenesis and in secretory pathways (25). However, the machinery behind triggering such changes is currently indistinct. One possible hypothesis described in a review by Fortini et al. is that the Fringe family of glycosyltransferases catalyzes the elongation of O-fucose by the addition of N-acetylgalactosamines on specific EGF-like repeats of the Notch extracellular domain glycosylation by a N-acetylgalactosaminytransferase (GlcNAC) to O-fructose of the Notch receptor’s extra-cellular domain, disrupting the activation efficacy of Notch to bind to its ligands (26). They further demonstrated that modification of Fringe proteins at the Notch receptor enhances its suitability to bind to a specific receptor in comparison to non-modified Notch receptors. This indicates the fact that post-transcriptional modifications of Notch, including glycosylation, deeply influence the efficacy of the Notch signaling (Figure 3). The findings of Li et al. indicated that the binding capacity of Notch is regulated by the presence of O-fucosylation sites, which in *Drosophila* photoreceptor cells promote differentiation defects, such as elevated neuronal apoptosis (27). While loss of function mutations such as fucosylation deletion in mouse and zebrafish are associated with increase in neuronal apoptosis and neuronal plasticity (28).

The second most crucial post-translational modification that greatly impacts the Notch signaling activation is proteolysis and proteolytic cleavage (Figure 3). Specific sites (S1-3) are present on receptors for the proteolytic processing that facilitate maturation and activation of Notch receptors. Notch’s pre-processing results in its activation and occurs in Golgi-complex, where the proteolytic cleavage is carried out by a furin-like convertase. However, for neuronal differentiation, cleavage at the S1 site is inhibited by Botch (29). The cleavage of Notch ECD at the S2 and S3 sites is induced by pro-enzymes like ADAM10 and γ-secretase which bring about ECD breakage and NICD internalization to the cytoplasm through endocytosis (11). The tight regulation of this process is carried out under the control of genes Numb and Sanpodo (30). This cytoplasmic movement is uni-directional, which through eliciting cytokine release promotes asymmetric neuronal differentiation as well as neurogenesis. One more proteolytic enzyme, α-adaplin, assists in internal trafficking of NICD by recruiting the endocytic AP-2 complex to the Numb and consequently promotes neurogenesis and fate-determination of NSCs (31). Studies have highlighted that the duo of AP-2 complex and α-adaplin facilitates the coupling of Sanpodo with Numb, which further causes the endocytosis of NICD and regulates the homeostasis of progenitor NSCs. Proteolytic cleavage is required for neuronal differentiation. However, to retain the potential of self-renewal, excessive Notch signaling is a posing threat (30). To deal with the deleterious outcomes of such scenarios, Notch signaling is impeded through the ubiquitylation of the PEST domain of NICD. It is established through various loss of function studies that the presence of the Notch receptor and its ligands are mandatory for the NSCs and a contrary scenario results in neuro-developmental defects, faulty differentiation and aberrant cell transfer in embryonic neuronal cells (28).
Notch signaling: Epigenetic modifications as modulators in neuronal differentiation and neurogenesis

Notch interplay with various regulatory pathways of cells is vital for modulation of neuronal cell expression. Both epigenetic alterations and the cross talk between different cellular pathways with Notch assist in NSCs proliferation, development and migration (32, 33). Figure 4 includes the schematic representation of histone modification at different stages of NPC development.

Epigenetic modifications such as DNA methylation, histone modifications and miRNA/LncRNA, have been documented to play an fundamental role in fate determination and differentiation of NSCs (34, 35). The whole scenario is still incomplete; however, compelling evidence has shed light on how these mechanisms play a role in mentoring the Notch signaling pathway (Figure 5).

Notch-driven DNA demethylation is necessary for neurogenesis activation in embryonic cells. Embryogenesis mediation by Notch signaling is dependent on Hes5 expression and the demethylation of Glial Cell Missing (GCM) determines Hes5 expression in NSCs (36). In vivo studies have demonstrated that the absence of GCM leads to abrogation of Notch signaling and impairment of neurogenesis; conversely GCM’s prolonged expression is associated with differentiation of embryonic neurons from early stage to more advanced stages in a series of transitions. The link between Notch signaling and DNA methylation was elucidated by a study conducted by Hitoshi et al. They demonstrated that the pattern of neuronal differentiation into astrocytes is determined by Notch signaling and DNA methylation interplay (36). During the mid-gestation period, transcription factor I-α is secreted by neuronal cells and induces demethylation of NOTCH1, RGMA and AKT1 genes which in turn furthers the differentiation of neural progenitors and brings about the physiological production of the astrocytes. Notch1 being the mediator of gene’s up-regulation also prompts the development of neuronal progeny (37). It has been demonstrated by various evidences that the process of DNA methylation is greatly influenced by the action of Notch1, Hes1 and Ngn2 which can in turn generate immense alterations in Notch signaling-mediated DNA methylation (38).

DNA methylation is the key process necessary for gliogenesis under the influence of Notch. NSCs require demethylation of HES5 via Gcm (glial cell missing). Demethylation promotes the activation of the Notch downstream signaling. Upregulation of Notch activity promotes gliogenesis. Activation of Notch in turn promotes isolation of DmmT1 that induces STAT activation, which in turn promotes development of astrocytes.

Histone modifications are the genetic indicators of transcription. Their influence is executed through chromatin modification, assisting in chromosome unwinding and recruitment of transcription factors. The defined
mechanisms, through utilizing which histone modification elicit responses are: phosphorylation, acetylation, ubiquitination and methylation (39). The key enzyme that mediates Notch-dependent transcription activation is Histone acetyltransferase (HAT) which functions through RBPj (40). HAT has also been reported to execute similar modifications in mice, referred as PCAF and GCN5 (41). In the absence of Notch signaling, RBP-Jc/CFB-1 functions as transcription suppressor in humans. CBF1 first recruits HDAC1 and SMRT and forms a repression complex of SMRT/HDAC with another corepressor, SHARP which directly suppresses Hes1 promoter activity and brings about inhibition of Notch mediated signaling (40, 42). HDAC1 role in suppressing Notch signaling in neurogenesis was also documented in zebra fish where suppression of Notch signaling is essential for switching from neuronal proliferation to differentiation (43). Sirt1, a deacetylase, forms a repression complex with LSD1, H4K16 and H3K4 (type of histone demethylases), which control the process of neurogenesis by acting on the Notch-Hes gene (44). The role of histone modifiers in activation and repression of Notch signaling is illustrated in Figure 6.

**Interplay of Notch with other pathways**

The process of neurogenesis cannot solely be triggered by Notch signaling; therefore, a crosstalk with other cellular pathways is essential for the maintenance of growth and differentiation of neuronal cells. The bone morphogenetic protein (BMP) pathway prevents glial cell differentiation and brings about the inhibition of neural growth in the primary neurogenesis phase. Upon interacting with the cell surface receptor, the phosphorylation activation of SMAD occurs (45). Like the Notch signaling pathway, the obligatory maintainer of the neuronal stem cells (NSCs), BMP signaling also imposes a particular latency on NSCs (46). Mainly because of sharing of common targets by both signaling pathways including the transcription factor HES family and DNA binding genes’ inhibitors (22, 47). Certain idleness might be posed by target gene sharing due to inhibition of unphosphorylated β-catenin where it induces the formation of trimeric complex Wnt/Lrp6/FZD, which makes use of axin and other factors responsible for phosphorylation (50). However, in GSK3 absence the Wnt’s interaction with frizzled (FZD) receptor, in the presence of Lrp6, is required for its activation. The role of Wnt signaling has been explored in the differentiation and programming of neurons (49). The chief element responsible for β-catenin ubiquitination in Wnt signaling is Glycogen synthetase kinase 3 (GSK3) which makes use of axin and other factors responsible for phosphorylation (50). However, in GSK3 absence the Wnt’s interaction with frizzled (FZD) receptor, in the presence of Lrp6, is required for its activation. The formation of trimeric complex Wnt/Lrp6/FZD, consequently leads to the prevention of β-catenin phosphorylation and further assists in cytoplasmic translocation of unphosphorylated β-catenin where it induces the transcription of the target genes (51). The interplay between Wnt and Notch signaling is in an agonistic manner where activation of one facilitates the activation of similar transcription factors. Wnt directly brings about the activation of the neuronal genes including Ngn1 and neuroD (genes acting as mediators of differentiation) whereas Notch-targeted Hes5 competes with Ngn1 and neuroD to block neuronal cell differentiation (23).

Among other signaling pathways, FOXO and Hippo interact with Notch signaling at different transcription levels to facilitate growth and differentiation of the neuronal crest. However, due to inadequacy of knowledge on these pathways’ explicit role in up-keep and differentiation of NSCs, further efforts are required for better understanding of their involvement (52).

**Notch signaling and gliomas**

The rate of neurogenesis declines with age. Mechanisms causing this decline have yet to be explored. However, it is considered that the involvement of numerous pathways, metabolic alterations, cell cycle regulation and epigenetic factors are behind this complex process. The association of Notch signaling and aging in neurogenesis has been highlighted in several studies. In aged mice, considerable decline in Notch expression has been reported, which is accompanied by decline of dentate gyrus’s NSCs differentiation (53). However, the quiescent NSCs are shown to be revived by kainic-induced seizures in aged mice. In *Drosophila* persistent elevated Notch signaling has negligible effect on old intermediate neuronal progenitors (INPs) while the slightly younger INPs activity is increased by elevated Notch signaling. Therefore, Notch signaling and its downstream target genes play an important role in the
self-renewal of NSCs (54).

**Glioblastoma**

The worldwide annual incidence rate of gliomas is high. Among malignant gliomas, the annual incidence rate of astrocytomas and mixed gliomas is 5 per 100,000 individuals (55, 56). Glioma characterization is done on the basis of disease severity and invasiveness into grade I to grade IV. Gliomas, according to classical division, are classified into primary and secondary glioblastomas (57, 58). Its aggressive behavior is because of the involvement of glioma stem cells (GSCs) that not only elevate its tumor potential but also effectively hamper effectively antitumor drugs (59). GSCs hijack the normal growth regulatory mechanism of cells and nurture alongside the neuronal cells (60). Studies have elucidated the role of Notch signaling in the development of GSCs (61). Mutations occurring in the Notch receptor or associated machinery can trigger aberrant Notch signaling that leads to the abnormal growth of the glial cell population (61). Furthermore, to ensure the active proliferation of glioblastoma cells, GSCs induce up-regulation of the Notch receptors after taking control of the cell regulatory mechanism (62). The control also capacitates GSCs to hamper the cell cycle progression, which induces chemotherapy resistance. Studies have also indicated the higher activity of Notch in primary glioblastoma cells as well as resistant glial cells. Furthermore, *in vitro* and *in vivo* studies have demonstrated abrogated Notch signaling as the key element for development of brain tumor and inhibition of Notch signaling leads to cell growth arrest (63). Contrarily, some studies have documented the tumor suppressive role of Notch signaling in gliomas (64). A recent study reported in pro-neural PDGF/P53 that knocking out of Notch signaling resulted in the viability of tumors, which hinted towards Notch role as tumor suppressor (63, 65). Additionally, mutations leading to Notch inactivation have been observed in patients with gliomas and also absence of Notch signaling has been associated with early tumor progression and overall survival. It can be formulated through these findings that the Notch signaling role in gliomas is bi-faceted and requires further explorations.

Glioblastoma multiforme, a grade IV glioma, is very aggressive and has the potential to spread very rapidly. This is the most common form of primary brain tumor, but it is also the most destructive. Glioblastoma multiforme (GBM) has a high rate of malignancy, infiltration and necrosis. GBM current treatment strategies involve surgical excision of tumor, followed by one-year long chemo and radiotherapy sessions. However, drastic side effects and poor survival outcomes accompany this treatment strategy (66). Genetic mutations in glioblastoma regulate a variety of cellular processes that favor tumor growth, development, differentiation, migration, invasion and angiogenesis. Usually, the deregulation of master regulators (including Notch, EGFR, TP53, PTEN and PDGFR) of vital cellular processes gives way to malignancy. Evidence of the fact that tumorous glial cells hijack Notch signaling components came from siRNA-based experimentation. SiRNA-assisted Notch 1 deprivation in glioma cell lines brought about decline in cell growth and elevation in apoptosis (67).
While Notch signaling inhibition resulted in increase in levels of glial fibrillary acidic protein (GFAP) and decrease in vimentin expression that caused increased growth of astrocytes and decline in endo-mesenchymal transition, respectively, in glioma cell lines (68).

It is evident from these findings that tumor progression requires maintenance of a stream of undifferentiated glial cells. That Notch1 plays an oncogenic role in gliomas has also been confirmed by xenograft studies in which inhibition of Notch1 and ligand Dll1 caused early demise of mice whereas knocking down of ligand Jagged1 imparted no influence on proliferation and overall survival (67). Notch1 and its paralog Notch2 had opposite effects on the growth and development of subcutaneously engrafted U251 and A172 glioma cell lines. Notch1 knock-down or Notch2 over-expression both had slightly different effects on the pattern of growth of glial cells in vitro (69). Under the influence of Notch, Tenascin C (TNC) has been reported to enhance cell migration in gliomas. Notch induced expression of transcription factor RBPj-κ which binds to TNC and lead to proliferation and migration of the GBM cell (70). The consequence of this transformation is increase in GBM based astrocytes number and decreased survival rates of patients (71). The outcome of these studies brings to spotlight the therapeutic as well as diagnostic potential of microRNAs for gliomas.

**Notch signaling and implications of MicroRNAs in gliomas**

MicroRNAs (miRNAs) are small, non-coding RNAs involved in post-transcriptional processes that inhibit gene translation or induce their destabilization and degradation. In collaboration with Notch signaling, miRNAs coordinate differential growth of neuronal cell as well as their stemness, maintaining regular balance between these biological states. Several miRNAs regulate neuronal differentiation expression via Notch. For instance, Hes1 is targeted by miR-9 and its expression is modulated through a negative feedback loop system (72, 73). It has been reported that miR-9 and its sister stand miR-9* regulate neuronal development by regulating a whole class of Notch receptors (74). Other miRNAs including miR-124 along with miR-9 have been demonstrated to be associated with Notch ligand expression. miR-124, in order to regulate the maintenance of the NSCs, interacts with Jagged-2 (60). Similarly, miR-let-7 promotes the differentiation of glial cell by interacting at the transcription site and targeting Hes-5 (60). Another microRNA, miR-34, by acting on Numb, has been elucidated to modulate the balance between self-renewal and differentiation of neuronal cell (75).

Aberrent expression of certain miRNAs in neuronal cells leads to development of glioma and glioblastoma. Table 1 and Table 2 consist of lists of miRNAs that play tumor-promoting and tumor-suppressive roles, respectively, by regulating Notch signaling. Wang et al. in this regard, demonstrated the crucial involvement of miR-33a in the maintenance of growth and development of GSCs. Confirmation through microarray-based analysis revealed that miR-33a targets phosphodiesterase 8A (PDE8A) and UV radiation resistance-associated gene (UVRAG), which function as negative modulators of Notch signaling along with cAMP-PKA signaling pathway. In particular, antagonizing miR-33a function in GSCs reduced self-renewal and tumor progression in an animal model, whereas over-expression of miR-33a in non-GICs promoted the display of features associated with GICs. This suggests miR-33a as a suitable target for the treatment of glioblastoma (76).

The miR-34 family is the most studied in GBM. Among mRNA targets of the miR-34 family are Notch1 and Notch2. In particular, both miR-34c-3p and miR-34c-5p were found to be down-regulated in GBM and lower levels correlate with a higher glioma grade. This is also supported by the fact that the over-expression of both miRNAs inhibit glioma invasion and only miR-34c-3p increases cell apoptosis and reduces Notch2 expression (46). Other tumor-suppressive miRNAs associated with Notch in GBM and belonging to the miR-34 family are miR-34a and miR-34a-5p. Both miRNAs target Notch1 and Notch2 as well as c-Met, CDK6 and EGFR. In this way they are able to reduce cell cycle progression and cell invasion (82, 83). Moreover, the role of miR-34a as a trans-differentiation mediator has been recently reported. Jin Z. et al. demonstrated that up-regulation of miR-34a induce a trans differentiation of GSCs into vascular endothelial cells (VECs) by targeting Notch1 and Dll1 (78).

Unlike miR-34c, miR-18a* contributes to GSC clonal proliferation and tumorigenicity directly down-regulating Dll3 levels and consequently enhancing Notch1 signaling. This activates ERK, thereby inducing SHH-GLI1-NANOG network which is essential for maintaining GSCs and enabling their self-renewal. This finding is indicative of the crucial role for miR-18a* in tumor growth and in controlling the switch between the self-renewing and non-self-renewing states of the GSCs (79).

The presence of low-level persistent expression of the Notch gene is necessary for the prolonged cellular growth of glioblastoma cells. The involvement of Notch signaling and its downstream signaling molecules in tumorous glial cells’ long-term survival is well-documented. Through the application of microarray analysis, Huber et al. established a link between glioblastoma cell aggressiveness and over-expression of miR-21. They demonstrated that miR-21-modulated Notch/Deltex pathway is requisite for invasiveness and growth of glioma cells. The culprit that activated Notch canonical signaling is DTX1, which further triggered RTK/PI3K/PKB and the MAPK/ERK mitotic pathways.

| Tumor promoting miRNA | Target | Reference |
|-----------------------|--------|-----------|
| miR-524-3p and miR-524-5p | EFGRvIII/c-MYC | (77) |
| miR-34a | Dll1 | (78) |
| miR-18a* | Dll3 | (79) |
| miR-21 | Mel-1 | (80) |
| miR-33a | PDE8A/UVRAG | (76) |
| miR-92a-3p | Notch domain | (81) |
| Let-7 | Hes5 | (60) |

Table 1. List of tumors promoting miRNAs that enhance Notch mediated proliferation.
hence, leading to the over-expression of anti-apoptotic proteins such as the Mci-1. Their finding revealed the direct association between miR-21 over-expression and elevated ERK expression which induces cellular growth and stemness of glioblastoma (80).

miR-107, a transcriptional target of p53, is downregulated in glioma samples and cell lines, in particular, p53-mutated U251 and A172 (notably, the miR-107 levels in U87 glioma cells expressing wild-type p53 are higher than p53-mutated U251 and A172). Chen and his colleagues via a lentiviral system approach and GFP assay demonstrated that under the influence of P53, miR-107 facilitates proliferation inhibition and cell cycle arrest at the G0–G1 phase in glioma cells, downregulating Notch2 and CDK6 expression. This points towards miR-107 anti-proliferative activity in brain tumors (84).

Notch signaling is indispensable for angiogenesis, tumor fate determination and survival. The very framework of cancer stemness is delineated by Notch and microRNAs’ interaction. Through bioinformatics and biological approaches, Chen and colleagues found that miR-524-5p, which expression is associated with grade and overall survival of gliomas, have direct regulatory control on the expression of two downstream targets of Notch pathway: Jagged1 and Hes1. Levels of both proteins are inversely correlated with miR-524-5p in gliomas. Knocking down of either of these partially phenocopied miR-524-5p re-expression (causing suppressed cell proliferation and invasion both in vitro and in vivo), whereas forced expression of Jagged1-1 or Hes1-1 reversed the effects of miR-524-5p on proliferation and invasion of glioma (85)(24).

The key cascade pathway perturbed in gliomas is epidermal growth factor receptor (EGFR) signaling. Recent findings imply the contribution of miR-524-3p and miR-524-5p in suppressing this pathway in gliomas. Both miRNAs are downregulated in the classical subtype of GBM and suppression was associated with EGFR overexpression and EGFRVIII mutation. Indeed, EGFR amplification/mutation can repress the expression of miR-524-5p, which re-expression becomes associated with grade and overall survival of gliomas, have direct regulatory control on the expression of two downstream targets of Notch pathway: Jagged1 and Hes1. Levels of both proteins are inversely correlated with miR-524-5p in gliomas. Knocking down of either of these partially phenocopied miR-524-5p re-expression (causing suppressed cell proliferation and invasion both in vitro and in vivo), whereas forced expression of Jagged1-1 or Hes1-1 reversed the effects of miR-524-5p on proliferation and invasion of glioma (85)(24).

The key cascade pathway perturbed in gliomas is epidermal growth factor receptor (EGFR) signaling. Recent findings imply the contribution of miR-524-3p and miR-524-5p in suppressing this pathway in gliomas. Both miRNAs are downregulated in the classical subtype of GBM and suppression was associated with EGFR overexpression and EGFRVIII mutation. Indeed, EGFR amplification/mutation can repress the expression of miR-524-5p, which re-expression becomes associated with grade and overall survival of gliomas. Knocking down of Jagged1-1 or Hes1-1 reversed the effects of miR-524-5p on proliferation and invasion of glioma (85)(24).

The finding of Kefas et al. further affirmed the interplay of microRNAs and Notch. They brought to light that down-expression of miR-145 enhances the expression of Bnip-3, a BH3-only protein upregulated by HIF1 in hypoxic region of tumors. The authors demonstrated that an overexpression of miR-145 inhibits Bnip-3 transduction, promoting glioma cell death by regulating Notch signaling pathway. In particular, the authors showed that the upregulation of miR-145 and knockdown of Bnip3 decrease protein expression of Notch1, Hes1, and p21 in glioma cells, while miR-145 downregulation and upregulation of Bnip3 increase the Notch1, Hes1, and p21 levels in glioma cells. Lastly, co-transfection of downregulated miR-145 and knockdown of Bnip3 decreased the protein levels of the Notch1-regulated proteins. This suggested that miR-145/Bnip3/Notch axis could represent a novel approach for the eradication of gliomas (89).

Different microRNAs trigger and inhibit the development of gliomas. However, a recent report has shed light on the microRNA that plays a bio-facet role in gliomas. miR-92a-3p was reported to be upregulated in human glioma samples but was less expressed in GSCs compared to glioma cells, suggesting that miR-92a-3p could serve as either an onco-miR or a tumor suppressor in different cell types. Sont et al. demonstrated that miR-92a-3p targets CDH1/β-catenin signaling in glioma cells, while Notch1/Akt signaling was the downstream pathway of miR-92a-3p in GSCs. These observations suggest that negative regulation of miR-92a-3p on the migration and invasion ability of glioma cells was partly by blocking the CDH1/β-catenin signaling pathway, while the reduction of Notch1 by specific siRNA could also inhibit the self-renewal ability of GSCs, suggesting that miR-92a-3p affects the maintenance of stemness of GSCs by down-regulating Notch1 expression (81).

**Table 2. List of tumor suppressor miRNAs that enhance Notch mediated apoptosis.**

| Tumor suppressor miRNA | Target            | Reference |
|------------------------|-------------------|-----------|
| miR-107                | CDK6/Notch 2      | (23)      |
| miR-524-5p             | Jagged 1/Hes1     | (24)      |
| miR-199-5p             | Hes1              | (25)      |
| miR-326                | Notch 1           | (26)      |
| miR-92a-3p             | B-Catenin         | (21)      |

For cancer stem cell growth and development, the importance of expression of microRNAs has been demonstrated in both a murine model of glioma and human glioma cells. However, recent advancement has brought to light that down-regulation of miR-145 enhances the expression of Bnip-3, a BH3-only protein upregulated by HIF1 in hypoxic region of tumors. The authors demonstrated that an overexpression of miR-145 inhibits Bnip-3 transduction, promoting glioma cell death by regulating Notch signaling pathway. In particular, the authors showed that the upregulation of miR-145 and knockdown of Bnip3 decrease protein expression of Notch1, Hes1, and p21 in glioma cells, while miR-145 downregulation and upregulation of Bnip3 increase the Notch1, Hes1, and p21 levels in glioma cells. Lastly, co-transfection of downregulated miR-145 and knockdown of Bnip3 decreased the protein levels of the Notch1-regulated proteins. This suggested that miR-145/Bnip3/Notch axis could represent a novel approach for the eradication of gliomas (89).

**Table 2. List of tumor suppressor miRNAs that enhance Notch mediated apoptosis.**

| Tumor suppressor miRNA | Target            | Reference |
|------------------------|-------------------|-----------|
| miR-107                | CDK6/Notch 2      | (23)      |
| miR-524-5p             | Jagged 1/Hes1     | (24)      |
| miR-199-5p             | Hes1              | (25)      |
| miR-326                | Notch 1           | (26)      |
| miR-92a-3p             | B-Catenin         | (21)      |
Conclusion

In this review, an outline of the Notch signaling pathway has been connected to neurogenesis and diseases in the brain, concisely depicting the Notch signaling network and its direction at various levels. Notch signaling and its components assume a substantial role not only in control of NSCs movement, but also in structural reorganization of the complex brain framework. In addition to this, Notch signaling regulates the cell cycle, generation of new neurons and monitors the infections that could occur to the CNS. In any case, through the element of Notch in the regulation of NSCs, preservation and differentiation are broadly acknowledged. The accurate molecular mechanism, even in this settled capacity, is not clear and needs further exploration. Notch signaling has been in the spotlight over the past two decades. New findings have related massive involvement of Notch signaling in human brain tumors such as the gliomas. Recent advances in the field of RNA-seq, microarray, high throughput technologies have enabled us to glance at the tiny molecules such as microRNAs in details. Numerous new studies have begun to shed light on the regulatory role of miRNAs in various cellular processes. However, the role of microRNAs in regulating Notch signaling and in gliomas is still bleak. With identification of key miRNAs and Notch signaling elements in gliomas, it is possible to design microRNA-based biomarkers for this complicated anomaly.

Several miRNAs have been reported to be expressed during specific stages of glioma; therefore, miRNAs could be implemented as diagnostic markers for the disease progression. Moreover, few species of miRNAs have been affiliated with the expression of targeted genes and thus play a regulatory role in protein synthesis. Targeting these miRNAs with anti-sense RNAs is a promising approach in devising new therapeutic strategies for cancer.

Over the years natural compounds have emerged as a therapeutic solution for various cancers. Natural compounds are a weapon of choice because of their limited side effects and reduced cytotoxicity compared to modern drug formulations and chemotherapy which produce limitless side effects and high cytotoxicity. The precision and accuracy of the natural compounds is still a debatable question. Natural compounds are highly target specific and have low cytotoxic effect. However, determining the efficacy of natural compound-derived drugs in hampering cellular growth in gliomas still requires many painstaking efforts. Poor survival, late diagnosis, limited therapeutic options are the hindrances that have hampered progress related to devising strategies for gliomas. Despite several advances made in the field of high throughout technology, RNA sequencing, single cell sequencing, chip and molecular biology, and efficient diagnosis of the neuronal malignancies, several stumbling blocks remain that are needed to be overcome in order to devise new therapeutic strategy for different brain related anomalies. Most challenging among them is designing an effective strategy for drug delivery beyond the blood brain barrier (90). Although numerous delivery methods have been tested but so far, no efficient strategy is available that could ensure thorough success. Other than that, the age of the patient, dreadful chemotherapy outcomes and surgical complications for tumors in deeper regions of brain still need to be addressed. Up to now, the efficacy of extracellular vesicles in delivering drugs for brain malignancies has not been demonstrated experimentally, which theoretically holds potential for overcoming the hurdle of the blood brain barrier. Apart from that, application of nano-therapeutics also seems to present an efficient treatment alternative (91), but natural compounds still present the best option considering minimal cytotoxicity (92, 93). So, development of sustainable drug delivery approach with low toxicity can bring us closer to devising effective therapeutics for brain malignancies. But all efficient treatment strategies are in vain if disease is not timely diagnosed, in which case miRNAs provide a far more valid approach toward early detection of cancer in brain. Unfortunately, the knowledge so far is insufficient to clearly comprehend the whole scenario. So, much more work is required to maximize our understanding and take advantage of the potentials of novel Notch signaling pathway in diagnostic and therapeutic approaches.

Funding
None

Conflicts of Interest
The authors declare no conflict of interest.

References

1. Dexter JS. The analysis of a case of continuous variation in Drosophila by a study of its linkage relations. The American Naturalist 1914; 48(576): 712-758.
2. Artavanis-Tsakonas S, Muskavitch M, Yedvobnick B. Molecular cloning of Notch, a locus affecting neurogenesis in Drosophila melanogaster. Proceedings of the National Academy of Sciences 1983; 80(7): 1977-1981.
3. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009; 137(2): 216-233.
4. Henrique D, Schweisguth F. Mechanisms of Notch signaling: a simple logic deployed in time and space. Development 2019; 146(3): dev172148.
5. Basak O, Giachino C, Fiorini E, MacDonald HR, Taylor V. Neurogenic subventricular zone stem/progenitor cells are Notch1-dependent in their active but not quiescent state. J Neurosci 2012; 32(16): 5654-5666.
6. Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci 2002; 25(1): 471-490.
7. Bellec K, Gicquel I, Le Borgne R. The Clathrin adaptor AP-1 and the Rab-stabilizing chaperone Stratum act in two parallel pathways to control the activation of the Notch pathway in Drosophila. bioRxiv 2019: 645580.
8. Reybey I, Fleming RJ, Fehon RG, Cherbas L, Cherbas P, Artavanis-Tsakonas S. Specific EGF repeats of Notch mediate interactions with Delta and Serrate: implications for Notch as a multifunctional receptor. Cell 1991; 67(4): 687-699.
9. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling—are we there yet? Nature reviews Drug discovery 2014; 13(5): 357.
10. Ogawa M. A New Type of O-Glucose Modification by POGLUT2 and POGLUT3 Controls Notch Signaling and Trafficking. Trends in Glycoscience and Glycotechnology 2019; 31(179): E53-E54.
11. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol 2000; 228(2): 151-165.
12. Jarrett SM, Seegar TC, Andrews M et al. Molecular basis for
feedback inhibition of Notch signaling by the Notch regulated ankyrin repeat protein NARAP. bioRxiv 2019: 645937.
13.Borggreve T, Oswald F. The Notch signaling pathway: transcriptional regulation at Notch target genes. Cell Mol Life Sci 2009; 66(10): 1631-1646.
14.Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001; 21(18): 6091-6101.
15.Okubo Y, Ohtake F, Igarashi K et al. Tuning of Neural Development Via Lateral Inhibition by Bi-Directional Notch-Delta Signaling. Available at SSRN 3351827 2019.
16.Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. The EMBO journal 1999; 18(8): 2196-2207.
17.Bertrand N, Castro DS, Guillemot F, Pronelen genes and the specification of neural cell types. Nature Reviews Neuroscience 2002; 3(7): 517.
18.Gao J, Van Meter M, Lopez SH et al. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically-heterogeneous mouse model of T-cell acute lymphoblastic leukemia. Disease models & mechanisms 2019; dmm. 040931.
19.Harris L, Guillemot F. HES1, two programs: promoting the quiescence and proliferation of adult neural stem cells. Genes & development 2019; 33(9-10): 479-6101.
20.Ross SE, Greenberg ME, Stiles CD. Basic helix-loop-helix factors in cortical development. Neuron 2003; 39(1): 13-25.
21.Nandagopal N, Santat LA, Elowitz MB. Cis-activation in the Notch signaling pathway. eLife 2019; 8: e57880.
22.Castro DS, Skowronska-Krawczyk D, Armant O et al. Pronuclear bHLH and Bnr proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. Dev Cell 2006; 11(6): 831-844.
23.Shimojo H, Ohtsuka T, Kageyama R. Oscillations in notch signaling regulate maintenance of neural progenitors. Neuron 2008; 58(1): 52-64.
24.Imayoshi I, Isomura A, Harima Y et al. Oscillatory control of factors determining multipotency and fate in mouse neural progenitors. Science 2013; 342(6163): 1203-1208.
25.Haines N, Irvine KD. Glycosylation regulates Notch signalling. Nature reviews Molecular cell biology 2003; 4(10): 786.
26.Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16(5): 633-647.
27.Li Y, Li L, Irvine KD. Baker NE. Notch activity in neural cells cells in developing and adult brains. Journal of Neuroscience 2010; 30(9): 3489-3498.
28.Goy J, Scully K, Zhu X et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007; 446(7138): 882.
29.Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. J Biol Chem 2000; 275(22): 17211-17220.
30.Kao H-Y, Ordentlich P, Koyano-Nakagawa N et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998; 12(15): 2269-2277.
31.Yamaguchi M, Tonou-Fujimori N, Komori A et al. Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development 2005; 132(13): 3027-3043.
32.Wang J, Scully K, Zhu X et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007; 446(7138): 882.
33.Ishino Y, Kumar A et al. Mammalian Gcm genes induce Hes5 expression by active DNA demethylation and induce neural stem cells. Nat Neurosci 2011; 14(8): 957.
34.Zhao Y, Ueba T, Christie BR et al. Mice lacking methyl-CpG binding protein 1 have deficits in adult neurogenesis and hippocampal function. Proceedings of the National Academy of Sciences 2003; 100(11): 6777-6782.
35.Hitoshi S, Ishino Y, Kumar A et al. Mammalian Gcm genes induce Hes5 expression by active DNA demethylation and induce neural stem cells. Nat Neurosci 2011; 14(8): 957.
36.Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001; 21(18): 6091-6101.
37.Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. J Biol Chem 2000; 275(22): 17211-17220.
38.Zhang Z, Gao F, Kang X et al. Exploring the potential relationship between Notch pathway genes expression and their promoter methylation in mice hippocampal neurogenesis. Brain Res Bull 2015; 113: 8-16.
39.Zeeshan Javed et al. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically-heterogeneous mouse model of T-cell acute lymphoblastic leukemia. Disease models & mechanisms 2019; dmm. 040931.
40.Harris L, Guillemot F. HES1, two programs: promoting the quiescence and proliferation of adult neural stem cells. Genes & development 2019; 33(9-10): 479-6101.
41.Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. J Biol Chem 2000; 275(22): 17211-17220.
42.Kao H-Y, Ordentlich P, Koyano-Nakagawa N et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev 1998; 12(15): 2269-2277.
43.Yamaguchi M, Tonou-Fujimori N, Komori A et al. Histone deacetylase 1 regulates retinal neurogenesis in zebrafish by suppressing Wnt and Notch signaling pathways. Development 2005; 132(13): 3027-3043.
44.Wang J, Scully K, Zhu X et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007; 446(7138): 882.
45.Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. J Biol Chem 2000; 275(22): 17211-17220.
46.Wu Z, Wu Y, Tian Y et al. Differential effects of miR-34c-3p and miR-34c-5p on the proliferation, apoptosis and invasion of glioma cells. Oncology letters 2013; 6(5): 1447-1452.
47.Imayoshi I, Sakamoto M, Yamaguchi M, Mori K, Kageyama R. Essential roles of Notch signaling in maintenance of neural stem cells in developing and adult brains. Journal of Neuroscience 2010; 30(9): 3489-3498.
48.Hatakeyama J, Kageyama R. Notch1 expression is spatiotemporally correlated with neurogenesis and negatively regulated by Notch1-independent Hes genes in the developing nervous system. Cereb Cortex 2006; 16(suppl. 1): i132-i137.
49.Zechner D, Fujita Y, Hülsken J et al. β-Catenin signals regulate transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine & growth factor reviews 2005; 16(3): 251-263.
50.Zechner D, Fujita Y, Hülsken J et al. β-Catenin signals regulate transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine & growth factor reviews 2005; 16(3): 251-263.
51.Komiya Y, Habas R. Wnt signal transduction pathways. Development 2005; 132(13): 3027-3043.
Neurosci 2010; 32(8): 1256-1264.
54. Ables JL, DeCarolis NA, Johnson MA et al. Notch1 is required for maintenance of the reservoir of adult hippocampal stem cells. J Neurosci 2010; 30(31): 10484-10492.
55. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta neuropathologica 2007; 114(2): 97-109.
56. Wen PY, Kesari S. Malignant gliomas in adults. New Engl J Med 2008; 359(5): 492-507.
57. Bralten LB, French PJ. Genetic alterations in glioma. Cancers 2011; 3(1): 1129-1140.
58. Yoshida J. Molecular neurosurgery using gene therapy to treat malignant glioma. Nagoya journal of medical science 1996; 59: 97-106.
59. Chen J, Li Y, Yu T-S et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012; 488(7412): 522.
60. Patterson M, Gaeta X, Loo K et al. let-7 miRNAs can act through notch to regulate human gliogenesis. Stem cell reports 2014; 3(5): 758-773.
61. Fan X, Mikolaenko I, Elhassan I et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64(21): 7787-7793.
62. Liu BB, Sievers C, Donohue LK et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell stem cell 2017; 20(2): 233-246. e237.
63. Suzuki H, Aoki K, Chiba K et al. Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 2015; 47(5): 458.
64. Giachino C, Boulay J-L, Ivanek R et al. A tumor suppressor function for notch signaling in forebrain tumor subtypes. Cancer Cell 2015; 28(6): 730-742.
65. Network CGAR. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. New Engl J Med 2015; 372(26): 2481-2498.
66. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 352(10): 987-996.
67. Purrow BW, Haque RM, Noel MW et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65(6): 2353-2363.
68. Kanamori M, Kawaguchi T, Nigro JM et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007; 106(3): 417-427.
69. Xu P, Zhang A, Jiang R et al. The different role of Notch1 and Notch2 in astrocytic gliomas. PloS one 2013; 8(1): e53654.
70. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis BA, Merlo A. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. PLoS One 2013; 8(2): e57793.
71. Sivasankaran B, Degen M, Ghaffari A et al. Tenascin-C is a novel survival and proliferation. Cancer Res 2009; 69(19): 7569-7576.
72. Bonev B, Pisco A, Papalopulu N. MicroRNA-9 reveals regional diversity of neural progenitors along the anterior-posterior axis. Developmental cell 2011; 20(1): 19-32.
73. Bonev B, Stanley P, Papalopulu N. MicroRNA-9 modulates Hes1 ultradian oscillations by forming a double-negative feedback loop. Cell reports 2012; 2(1): 10-18.
74. Roese-Koerner B, Stappert L, Berger T et al. Reciprocal Regulation between Bifunctional miR-9/9* and its Transcriptional Modulator Notch in Human Neural Stem Cell Self-Renewal and Differentiation. Stem cell reports 2016; 7(2): 207-219.
75. Fineberg SK, Datta P, Stein CS, Davidson BL. MiR-34a represses Numb1 in murine neural progenitor cells and antagonizes neuronal differentiation. PloS one 2012; 7(6): e38562.
76. Wang H, Sun T, Hu J et al. miR-33a promotes glioma-initiating cell self-Renewal via PKA and NOTCH pathways. The Journal of clinical investigation 2014; 124(10): 4489-4502.
77. Zhao K, Wang Q, Wang Y et al. EGFR/c-myc axis regulates TGFβ/Hippo/Notch pathway via epigenetic silencing miR-524 in gliomas. Cancer letters 2017; 406: 12-21.
78. Jin Z, Zhan T, Tao J et al. MicroRNA-34a induces transdifferentiation of glioma stem cells into vascular endothelial cells by targeting Notch pathway. Bioscience, biotechnology, and biochemistry 2017; 81(10): 1899-1907.
79. Turchi L, Debruyne DN, Almairac F et al. Tumorigenic potential of mir-18A* in glioma initiating cells requires NOTCH-1 signaling. Stem Cells 2013; 31(7): 1252-1265.
80. Huber RM, Rajski S, Sivasankaran B, Moncayo G, Hemmings BA, Merlo A. Deltex-1 activates mitotic signaling and proliferation and increases the clonogenic and invasive potential of U373 and LN18 glioblastoma cells and correlates with patient survival. Cancer Res 2009; 69(19): 7569-7576.
81. Song H, Zhang Y, Liu N, Zhao S, Kong Y, Yuan L. miR-92a-3p exerts various effects in glioma and glioma stem-like cells specifically targeting CDH1/β-catenin and Notch-1/Akt signaling pathways. International journal of molecular sciences 2016; 17(11): 1799.
82. Li Y, Guessous F, Zhang Y et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009; 69(19): 7569-7576.
83. Di Bari M, Bevilacqua V, De Jaco A et al. Mir-34a-5p mediates cross-talk between M2 muscarinic receptors and Notch-1/EGFR pathways in U87MG glioblastoma cells: implication in cell proliferation. International journal of molecular sciences 2018; 19(6): 1631.
84. Chen L, Zhang R, Li P et al. PS3-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CKD6 and Notch-2. Neuroscience letters 2013; 534: 327-332.
85. Chen L, Zhang W, Yan W et al. The putative tumor suppressor miR-524–5p directly targets Jagged-1 and Hes-1 in glioma. Carcinogenesis 2012; 33(11): 2276-2282.
86. Ruan J, Lou S, Dai Q, Mao D, Ji J, Sun X. Tumor suppressor miR-181e attenuates proliferation, invasion, and self-renewal abilities in glioblastoma. Neuroreport 2015; 26(2): 66-73.
87. Wong H-KA, El Fatimy R, Onodera C et al. The Genome Genome Atlas analysis predicts microRNA for targeting cancer growth and vascularization in glioblastoma. Mol Ther 2015; 23(7): 1234-1247.
88. Kefas B, Comeau L, Floyd DH et al. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. Journal of Neuroscience 2009; 29(48): 15161-15168.
89. Du Y, Li J, Xu T, Zhou D-D, Zhang L, Wang X. MicroRNA-145 induces apoptosis of glioma cells by targeting BNP3 and Notch signaling. Oncotarget 2017; 8(37): 61510.
90. Corada M, Orsenigo F, Bhat GP et al. Fine-Tuning of Sox17 and Canonical Wnt Coordinates the Permeability Properties of the Blood-Brain Barrier. Circul Res 2019; 124(4): 511-525.
91. Kim J, Ahn SL, Kim Y. Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. Journal of Industrial and Engineering Chemistry 2019.
92. Maués L, Alves G, Couto N et al. Flavonoids from the Amazon plant Brosimum acutifolium induce C6 glioma cell line apoptosis by disrupting mitochondrial membrane potential and reducing AKT phosphorylation. Biomed Pharmacother 2019; 113: 108728.
93. Sansalone L, Veliz EA, Myrthil NG et al. Novel Curcumin Inspired Bis-Chalcone Promotes Endoplasmic Reticulum Stress and Glioblastoma Neurosphere Cell Death. Cancers 2019; 11(3): 357.